Clinical Application of Pharmacogenomics

@article{Ma2012ClinicalAO,
  title={Clinical Application of Pharmacogenomics},
  author={Joseph D. Ma and Kelly C. Lee and Grace M. Kuo},
  journal={Journal of Pharmacy Practice},
  year={2012},
  volume={25},
  pages={417 - 427}
}
The purpose of this review is to discuss the clinical application of pharmacogenomics for select drug therapies (eg, proton pump inhibitors [PPIs], codeine, and carbamazepine) and to highlight limitations and challenges that preclude implementation of pharmacogenomics into clinical practice. Genetic polymorphisms of cytochrome P450 (CYP) enzymes and the presence of the human leukocyte antigen (HLA)-B*1502 allele influence drug disposition and/or response. A portion of PPI pharmacokinetic and… 

Tables from this paper

Pharmacogenomics: Clinical Perspective, Strategies, and Challenges

The objective of this chapter is to discuss the basic principle of PGx and its application and also to put forward the ethical, social, technological, and economic challenges in the way of PGX.

Towards personalized opioid dosing: A concise overview of CYP polymorphisms

Patients who have genotype polymorphisms in these enzymes are phenotypically (clinically) poor, intermediate, extensive, or ultra-rapid metabolizers, affecting how rapidly or to what extent an individual patient metabolizes opioids.

CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine

The incidence of PM status by phenotype following administration of omeprazole/esomeprazole (known inhibitors of CYP2C19) was 10-fold higher than those who are genetically PMs in the general population, which could have critical clinical implications for personalizing medications primarily metabolized by CYP1C19.

CYP 2 C 19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole : Clinical Implications for Personalized Medicine s

The incidence of PM status by phenotype following administration of omeprazole/esomeprazole was 10-fold higher than those who are genetically PMs in the general population, which could have critical clinical implications for personalizing medications primarily metabolized by CYP2C19.

LightSNiP assay is a good strategy for pharmacogenetics test

The advantages of real-time PCR assays for the detection of three SNPs selected for their involvement in DPD and UGT1A1 enzymes regulations and not of practical use for small to medium size laboratories are described.

Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs

  • O. Badary
  • Medicine, Biology
    The pharmacogenomics journal
  • 2021
The available human genome interactions with some promising repurposed drugs for COVID-19 management, including chloroquine, azithromycin, lopinavir/ritonavir, and remdesivir are reviewed.

Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites

Along with the partial impacts on the biotransformation of clomiphene and its metabolites by CYP2D6 genetic polymorphism, further studies on the effects of other CYP enzymes in a multiple-dosing condition can provide more definite evidence for the inter-individual variabilities in clomIPhene pharmacokinetics and/or drug response.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine

This review focuses on the potentiality, reliability and limitations of the DMET™ (Drug Metabolism Enzymes and Transporters) Plus as pharmacogenomic drug metabolism multi-gene panel platform for selecting biomarkers in the final aim to optimize drugs use and characterize the individual genetic background.

The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-13C breath test in GERD patients: clinical relevance for personalized medicine

The concommitant use of omeprazole/esomeprazole could have critical clinical relevance in individualizing medications metabolized primarily by CYP2C19 such as PPI, clopidogrel, phenytoin, cyclophosphamide, thalidomide, citalopram, clonazepam, diazepam, proguanil, tivantinib etc.
...

References

SHOWING 1-10 OF 115 REFERENCES

Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)

  • U. Klotz
  • Medicine, Biology
    European Journal of Clinical Pharmacology
  • 2008
It can be concluded that CYP2C19 polymorphisms will have less impact for esomeprazole if compared to omeprazole, and a larger contribution of CYP3A4 to the overall metabolic clearance of Eur J Clin Pharmacol (2009) 65:1–2 DOI 10.1007/s00228-008-0571-x.

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication

  • I. Cascorbi
  • Biology
    European journal of clinical investigation
  • 2003
Since there is evidence that deteriorated drug elimination partly accounts for drug side‐effects, CYP2D6 genotyping could contribute to an individualized and therefore optimized drug therapy.

The clinical role of cytochrome p450 genotypes in Helicobacter pylori management

This first pharmacogenomics study on the influence of different CYP genotypes on H. pylori therapy suggests that, as in Asian populations, CYP2C19 genotype patterns are probably also relevant in Caucasians receiving H.pylori eradication regimens that include omeprazole.

Genetic Predictors of the Clinical Response to Opioid Analgesics

This review uses a candidate gene approach to identify possible pharmacogenetic modulators of opioid therapy, and discusses these modulators together with demonstrated genetic causes for the

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

The intricate genetics of the CYP2D6 polymorphism is becoming apparent at ever greater detail, applications in clinical practice are still rare, and more clinical studies are needed to show where patients benefit from drug dose adjustment based on their genotype.

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

  • S. ShiU. Klotz
  • Medicine, Biology
    European Journal of Clinical Pharmacology
  • 2008
This update of pharmacokinetic, pharmacodynamic, and clinical data will provide the necessary guide by which to select between the various PPIs that differ—based on pharmacodynamic assessments—in their relative potencies.

A Pharmacogenomics Primer

  • M. Court
  • Biology, Medicine
    Journal of clinical pharmacology
  • 2007
The purpose of this review is to provide the clinical pharmacologist with a primer on the principles and molecular mechanisms underlying pharmacogenomics, and the methods currently being used to discover novel pharmacogenomic biomarkers and then apply these to clinical practice.

Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.

A comparative in vitro study was conducted using the human liver microsomes and newly developed anti-human CYP antibodies, and the relative contribution of CYP2C19 on total metabolism of 3 PPIs elucidated herein coincided with the CYP1C19 genotype-dependent pharmacokinetics.

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

The observed differences in omeprazole AUC(infinity) suggest that the CYP2C19*17 allele is an important explanatory factor behind individual cases of therapeutic failure, and may be associated with subtherapeutic drug exposure.
...